RESUMO
Los Institutos Nacionales de Salud (INS) miembros de la Red Regional Latinoamericana de la Asociación Internacional de Institutos Nacionales de Salud Pública, reunidos en forma presencial en la sede del Instituto Nacional de Salud Pública de México, en la Ciudad de Cuernavaca, los días 5 al 7 de octubre de 2022, contando con la participación de los directores o representantes de los INS de (...).
RESUMO
The huge impact of SARS-CoV-2 infections on organ transplant recipients makes it necessary to optimize vaccine efficacy in this population. To effectively implement multiple strategies, it is crucial to understand the performance of each type of available vaccine. In our study, the antibody titer was measured, and the presence of antibodies against SARS-CoV-2 was evaluated after 90 days of immunization; furthermore, the differences between hybrid immunity, immunity by vaccination, and immunosuppressant type were identified. As a result, of the patients included in this study (n = 160), 53% showed antibodies against SARS-CoV-2 90 days after the first dose in patients who had completed the vaccination schedule. Antibody titers were higher in patients with hybrid immunity, and the proportion of nonresponsive patients was higher among those who received the immunosuppressant belatacept in their post-transplant regimen (P = .01). Only 15% of patients treated with this medicine seroconverted and patients vaccinated with CoronaVac and treated with belatacept showed no response. In conclusion, a reduced response to vaccines against SARS-CoV-2 was identified in the transplant population, and this response varied with the type of vaccine administered and the immunosuppressive treatment.
Assuntos
Vacinas contra COVID-19 , COVID-19 , Imunossupressores , Humanos , Abatacepte , Anticorpos , Anticorpos Antivirais , COVID-19/prevenção & controle , Imunossupressores/efeitos adversos , SARS-CoV-2 , VacinaçãoRESUMO
To mitigate the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), vaccines have been rapidly developed and introduced in many countries. In Colombia, the population was vaccinated with four vaccines. Therefore, this research aimed to determine the ability of the vaccines introduced in the National Vaccination Plan to prevent SARS-CoV-2 infection and induce seroconversion and sought to investigate the longevity of antibodies in the blood. We conducted a prospective, nonprobabilistic, consecutive cross-sectional cohort study in a population with access to vaccination with CoronaVac, Ad26.COV2.S, AZD1222, and BNT162b2 from March 2021 to March 2022. The study included 1327 vaccinated people. A plurality of participants were vaccinated with BNT162b2 (36.1%; n = 480), followed by Ad26.COV2.S (26.9%; n = 358), CoronaVac (24%; n = 331), and AZD1222 (11.9%; n = 158). The crude seroprevalence on day zero varied between 18.1% and 57.8%. Participants who received BNT162b2 had a lower risk of SARS-CoV-2 infection than those who received the other vaccines. Participants who were immunized with BNT162b2 and AZD1222 had a higher probability of losing reactivity on day 210 after receiving the vaccine.
RESUMO
Introduction: Monkeypox virus (MPXV) is an enveloped double-stranded DNA virus with a genome of approximately 197.209 bp. The current classification divides MPXV into three clades: Clade I (Central African or Congo Basin clade) and clades IIa and IIb (West African clades). Objective: To report the complete genome and phylogenetic analysis of a human monkeypox case detected in Colombia. Materials and methods: Exudate from vesicular lesions was obtained from a male patient with recent travel history to Spain. A direct genomic approach was implemented in which total DNA from the sample was purified through a column-based method, followed by sequencing on the Nanopore GridION. Reads were aligned against the MPXV reference genome using minimap2 v.2.24 and phylogenetic inference was performed using maximum likelihood estimation. Results: A total of 11.951 reads mapped directly to a reference genome with 96.8% of coverage (190.898 bp). Conclusion: Phylogenetic analysis of the MPXV circulating in Colombia demonstrated its close relationship to clade IIb responsible for the multi-country outbreak in 2022.
Introducción. El virus de la viruela del mono (MPXV) está compuesto por un genoma de ADN bicatenario, aproximadamente, de 197.209 pb. La clasificación actual agrupa el MPXV en tres clados: clado I (de la cuenca del Congo en África central), y clados IIa y IIb (de África occidental). Objetivo. Reportar el genoma completo y el análisis filogenético de un caso humano de viruela símica detectado en Colombia. Materiales y métodos. Se obtuvo exudado de lesiones vesiculares de un paciente varón con el antecedente de un viaje reciente a España. Se implementó un enfoque directo, en el cual se purificó el ADN total de la muestra mediante un método basado en columnas, seguido de la secuenciación directa en la plataforma Nanopore GridION. Las lecturas se alinearon con el genoma de referencia del MPXV, utilizando minimap2, v.2.24, y la inferencia filogenética fue realizada mediante la estimación por máxima verosimilitud. Resultados. Un total de 11.951 lecturas se alinearon directamente con el genoma de referencia con una cobertura del 96,8 % (190.898 pb). Conclusión. El análisis filogenético del MPXV circulante en Colombia demostró su estrecha relación con el clado de África occidental (clado IIb) responsable del brote en múltiples países en el 2022.
Assuntos
Monkeypox virus , Sequenciamento por Nanoporos , Filogenia , ColômbiaRESUMO
Project Vigilancia de Embarazadas con Zika (VEZ), an intensified surveillance of pregnant women with symptoms of the Zika virus disease (ZVD) in Colombia, aimed to evaluate the relationship between symptoms of ZVD during pregnancy and adverse pregnancy, birth, and infant outcomes and early childhood neurodevelopmental outcomes. During May-November 2016, pregnant women in three Colombian cities who were reported with symptoms of ZVD to the national surveillance system, or with symptoms of ZVD visiting participating clinics, were enrolled in Project VEZ. Data from maternal and pediatric (up to two years of age) medical records were abstracted. Available maternal specimens were tested for the presence of the Zika virus ribonucleic acid and/or anti-Zika virus immunoglobulin antibodies. Of 1213 enrolled pregnant women with symptoms of ZVD, 1180 had a known pregnancy outcome. Results of the Zika virus laboratory testing were available for 569 (48.2%) pregnancies with a known pregnancy outcome though testing timing varied and was often distal to the timing of symptoms; 254 (21.5% of the whole cohort; 44.6% of those with testing results) were confirmed or presumptive positive for the Zika virus infection. Of pregnancies with a known outcome, 50 (4.2%) fetuses/infants had Zika-associated brain or eye defects, which included microcephaly at birth. Early childhood adverse neurodevelopmental outcomes were more common among those with Zika-associated birth defects than among those without and more common among those with laboratory evidence of a Zika virus infection compared with the full cohort. The proportion of fetuses/infants with any Zika-associated brain or eye defect was consistent with the proportion seen in other studies. Enhancements to Colombia's existing national surveillance enabled the assessment of adverse outcomes associated with ZVD in pregnancy.
RESUMO
COVID-19 pandemics has led to genetic diversification of SARS-CoV-2 and the appearance of variants with potential impact in transmissibility and viral escape from acquired immunity. We report a new and highly divergent lineage containing 21 distinctive mutations (10 non-synonymous, eight synonymous, and three substitutions in non-coding regions). The amino acid changes L249S and E484K located at the CTD and RBD of the Spike protein could be of special interest due to their potential biological role in the virus-host relationship. Further studies are required for monitoring the epidemiologic impact of this new lineage.
RESUMO
Resumen | Introducción. El deseo de mejorar la apariencia física mediante métodos sencillos y económicos, ha generado la aplicación indiscriminada de sustancias modelantes y, con ello, el surgimiento de la alogenosis iatrogénica, enfermedad cada vez más prevalente en Latinoamérica. Objetivo. Describir las características epidemiológicas y los efectos adversos de las sustancias modelantes en un grupo de pacientes de Cali, Colombia. Materiales y métodos. Se hizo una revisión retrospectiva de las historias clínicas de los pacientes que acudieron a consulta por complicaciones producidas por sustancias modelantes durante un sexenio. Resultados. Se incluyeron 1.322 pacientes, 95,5 % de ellos mujeres. Las edades oscilaron entre los 19 y los 83 años, con una media de 39 años. El sitio anatómico de infiltración con sustancias modelantes con mayor frecuencia de efectos adversos, fueron los glúteos. La asimetría y el aumento del volumen en el sitio infiltrado fueron los signos más comunes, en tanto que el dolor, las alteraciones del ánimo y la depresión o la ansiedad fueron los síntomas más percibidos. El 33,6 % de los pacientes desconocía la sustancia aplicada y el 28,1 % refirió haberse aplicado biopolímeros. La mayoría de estos procedimientos estuvo a cargo de personal sin la debida formación. Conclusiones. Estos pacientes requieren la atención de equipos multidisciplinarios para establecer alternativas de tratamiento que mejoren su calidad de vida. Además, se necesitan la regulación de los establecimientos, y las medidas de vigilancia, inspección y control en la importación y el uso de estas sustancias.
Abstract | Introduction: The desire to improve one's physical appearance through simple and economical methods has resulted in the indiscriminate application of modeling substances. As a result, iatrogenic allogenosis has emerged as an increasingly prevalent disease in Latin America. Objective: To describe the epidemiological characteristics and adverse effects arising from the use of modeling substances in a group of patients from Cali, Colombia. Materials and methods: We conducted a retrospective review of the medical records of patients who consulted for complications arising from the use of modeling substances during a six-year period. Results: A total of 1,322 patients were included of whom 95.5% were women. Patients' ages ranged from 19 to 83 years, with an average of 39 years. The most infiltrated anatomical site showing adverse effects due to modeling substances was the buttocks. The asymmetry and increased volume of the infiltrated site were the most common signs while pain, mood disturbances, and depression or anxiety were the most commonly perceived symptoms. A total of 41.8% of patients ignored what substances they had received, and 28.5% received biopolymers; these procedures were mostly performed by non-qualified personnel. Conclusions: The care of these patients requires multidisciplinary teams to establish treatment alternatives to improve their quality of life. In addition, the regulation of establishments, as well as the surveillance, inspection, and control of the imports and use of these substances should be warranted.
Assuntos
Biopolímeros , Doença Iatrogênica , Procedimentos de Cirurgia Plástica , Estética , Contraindicações de ProcedimentosRESUMO
Coronavirus disease (COVID-19) in Colombia was first diagnosed in a traveler arriving from Italy on February 26, 2020. However, limited data are available on the origins and number of introductions of COVID-19 into the country. We sequenced the causative agent of COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), from 43 clinical samples we collected, along with another 79 genome sequences available from Colombia. We investigated the emergence and importation routes for SARS-CoV-2 into Colombia by using epidemiologic, historical air travel, and phylogenetic observations. Our study provides evidence of multiple introductions, mostly from Europe, and documents >12 lineages. Phylogenetic findings validate the lineage diversity, support multiple importation events, and demonstrate the evolutionary relationship of epidemiologically linked transmission chains. Our results reconstruct the early evolutionary history of SARS-CoV-2 in Colombia and highlight the advantages of genome sequencing to complement COVID-19 outbreak investigations.
Assuntos
COVID-19/epidemiologia , COVID-19/virologia , Genoma Viral , Genômica/métodos , Filogenia , SARS-CoV-2/genética , Colômbia/epidemiologia , Humanos , Reprodutibilidade dos TestesRESUMO
The use of the eHealth has become feasible and acceptable in a variety of fields and contexts in Colombia. This article reports on the Colombian experience using eHealth tools applied to cancer, as well as the challenges, emerging trends, and positive outcomes related to the use of information technology and communication in the national health system. One of these outcomes has been Colombia's National Cancer Information System, in place since 2012, which is the result of political action and strategies focused on applying these innovative technologies in the field of health. The final judgment will depend of the extent to which it is possible to guide timely, effective, and coordinated interventions to optimize care for people with cancer, improve their quality of life, and significantly reduce inequalities. Once this is achieved, the next step should be to replicate the experience and apply eHealth-based tools more broadly in the contexts and fields that the country and the Region require.
Assuntos
Informática Médica , Neoplasias , Telemedicina/organização & administração , Colômbia , HumanosRESUMO
El uso de la eSalud es factible y aceptable en muy variados temas y contextos en Colombia. En este artículo se expone la experiencia colombiana en el uso de las herramientas de eSalud aplicadas al cáncer, así como los retos, las tendencias emergentes y los efectos positivos relacionados con el uso de las tecnologías de la información y las comunicaciones en el Sistema Nacional de Salud. Como resultado, en Colombia se cuenta desde 2012 con el Sistema de Información Nacional en Cáncer, resultado de acciones políticas y estrategias dirigidas a aplicar estas novedosas tecnologías en la salud. La valoración final dependerá de la medida en que se logre orientar intervenciones oportunas, eficaces y articuladas para optimizar la atención de las personas con cáncer, mejorar su calidad de vida y reducir significativamente las desigualdades. De lograrse, el siguiente paso debe ser replicar esta experiencia y aplicar las herramientas basadas en eSalud de forma más amplia en los contextos y temas que el país y la Región requieren.
The use of the eHealth has become feasible and acceptable in a variety of fields and contexts in Colombia. This article reports on the Colombian experience using eHealth tools applied to cancer, as well as the challenges, emerging trends, and positive outcomes related to the use of information technology and communication in the national health system. One of these outcomes has been Colombia's National Cancer Information System, in place since 2012, which is the result of political action and strategies focused on applying these innovative technologies in the field of health. The final judgment will depend of the extent to which it is possible to guide timely, effective, and coordinated interventions to optimize care for people with cancer, improve their quality of life, and significantly reduce inequalities. Once this is achieved, the next step should be to replicate the experience and apply eHealth-based tools more broadly in the contexts and fields that the country and the Region require.
